BioXcel Therapeutics

General Information

BioXcel Therapeutics, Inc., or BTI, is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.

Employees: 4
Founded: 2017
Contact Information
Address 780 East Main Street, Branford, CT 06405, US
Phone Number (203) 643-8060
Web Address
View Prospectus: BioXcel Therapeutics
Financial Information
Market Cap $172.1mil
Revenues $0 mil (last 12 months)
Net Income $-4.5 mil (last 12 months)
IPO Profile
Symbol BTAI
Exchange NASDAQ
Shares (millions): 5.5
Price range $11.00 - $11.00
Est. $ Volume $60.0 mil
Manager / Joint Managers Barclays/ UBS Investment Bank/ BMO Capital Markets
CO-Managers Canaccord Genuity
Expected To Trade: 3/8/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change